Ignite Creation Date:
2024-06-16 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06428409
Status:
RECRUITING
Last Update Posted:
2024-07-03
First Post:
2024-05-20
Brief Title:
A Clinical Study of MK-2870 Alone or With Chemotherapy to Treat Gastrointestinal Cancers MK-9999-02A
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
A Phase 12 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Researchers want to learn if sacituzumab tirumotecan MK-2870 alone or with chemotherapy can treat certain gastrointestinal GI cancers The GI cancers being studied are either advanced the cancer has spread to other parts of the body or unresectable the cancer cannot be removed with surgery The goals of this study are to learn
About the safety and how well people tolerate sacituzumab tirumotecan alone or with chemotherapy
How many people have the cancer respond get smaller or go away to treatment
About the safety and how well people tolerate sacituzumab tirumotecan alone or with chemotherapy
How many people have the cancer respond get smaller or go away to treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| U1111-1298-8273 | OTHER | WHOUTN | None |
| MK-9999-02A | OTHER | None | None |
| 2023-508703-21 | OTHER | None | None |
| jRCT2031240178 | REGISTRY | None | None |